Resources/MoCRA §609(b): Anticipated US Fragrance Allergen Labeling Requirements
MoCRA §609(b): Anticipated US Fragrance Allergen Labeling Requirements
Disclaimer: The information provided in this guide is for educational and regulatory context purposes only and does not constitute formal legal advice. Compliance requirements can vary based on formulation, regional authority updates, and specific product claims. Consult a certified regulatory affairs professional or specialized legal counsel for official filings.
The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) significantly updates cosmetic regulation in the United States. Specifically, MoCRA §609(b) (21 U.S.C. §364e(b)) directs the Food and Drug Administration (FDA) to establish regulations for the disclosure of fragrance allergens in cosmetic products — this rulemaking is ongoing and not yet finalized, so no fragrance allergen labeling requirement is currently mandatory in the US. Once finalized, it will introduce a new layer of labeling complexity for brands operating in the US market, moving towards a system more aligned with existing international frameworks.
MoCRA's Mandate for Fragrance Allergen Disclosure
MoCRA §609(b) requires the FDA to propose and finalize regulations identifying fragrance allergens that must be disclosed on cosmetic product labels — that rulemaking has not yet concluded. Once finalized, it will mark a significant shift from previous US cosmetic labeling practices, where fragrance ingredients could often be listed simply as "fragrance" or "parfum." The intent is to enhance consumer safety by providing greater transparency regarding potential sensitizers present in cosmetic formulations.
- The FDA is tasked with establishing a list of specific fragrance allergens requiring disclosure.
- The regulations will define the threshold concentrations at which these allergens must be declared.
- The disclosure method (e.g., inclusion in the ingredient list, separate allergen statement) will be specified by the FDA.
- This requirement applies to cosmetic products distributed or sold in the United States.
Implications for Formulators and Regulatory Teams
For R&D formulation chemists and regulatory affairs directors, MoCRA §609(b)'s anticipated rulemaking is worth preparing for now, even though it is not yet mandatory. Brands will need to obtain detailed ingredient breakdowns from their fragrance suppliers to identify any substances on the FDA's forthcoming allergen list. This will impact formulation decisions, supplier relationships, and ultimately, product labeling strategies.
- **Supplier Data:** Ensure robust data exchange with fragrance suppliers to identify individual allergen components.
- **Formulation Review:** Re-evaluate existing and new formulations for the presence and concentration of identified fragrance allergens.
- **Labeling Updates:** Prepare for potential label revisions to comply with the FDA's specific disclosure requirements.
- **Market Alignment:** Consider how US requirements may align with or diverge from existing allergen labeling in other markets, such as the EU Cosmetic Regulation's Annex III restricted substances.
To navigate the evolving landscape of MoCRA §609(b), regulatory and formulation teams should actively monitor FDA announcements regarding the proposed and final rules — none of which have been finalized yet. The specific list of allergens, their thresholds, and the exact labeling format will be critical details for ensuring compliance once published.
For the most current status on MoCRA §609(b) fragrance allergen requirements, including the FDA's established list of allergens and their specific disclosure thresholds once published, utilize The Molecule Lab's compliance engine. You can search for specific ingredients and track regulatory updates in your workspace or through our public-search feature to stay current as the rulemaking progresses.
This content was generated by AI. Always verify the information before use.